Two biosimilars developed under the Teva - Alvotech partnership have been granted FDA approval with interchangeability, including SELARSDI. In February 2024, the FDA approved SIMLANDI ® ...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. , and Alvotech today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDItm (ustekinumab-aekn) ...

The U.S. FDA has approved SELARSDI (ustekinumab-aekn) as interchangeable with the reference biologic Stelara® (ustekinumab) in all presentations matching the reference product, effective as of April ...

The product is indicated for use in children and adolescents aged 2 to 17 years with insufficient efficacy or intolerance of methotrexate ... in the form of a pre-filled 1 ml syringe with 25 mg/ml ...

Some types of PD-1 and PD-L1 inhibitors are available as subcutaneous injections that a cancer care professional injects into fat under the skin. These subcutaneous medications include ...

When selecting needles to vaccinate or treat cattle, there are several factors to consider to make the right decisions for overall herd health and best management practices.

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a subcutaneous injectable version of the cancer drug nivolumab (Opdivo, Bristol Myers Squibb). NHS England said it would ...

Using the latest data and perspectives, an international expert panel releases updated recommendations for optimal insulin ...

For people with diabetes who inject insulin, the syringe and needle size can make a big difference in comfort and staying on track with steady blood sugar levels. According to a 2024 statistics ...

A subcutaneous formulation of MSD's top-selling cancer immunotherapy, Keytruda, was non-inferior to the current intravenous version in a head-to-head trial, setting up regulatory filings.

With the safePICO self-fill blood gas syringe, you can improve your mixing and get results you can trust. Mixing ball helps you obtain a homogeneous sample SafeTIPCAP minimizes the risk of blood ...

Apellis' C3 inhibitor Empaveli (pegcetacoplan) is also approved for PNH, and is given by subcutaneous infusion, but remains a relatively minor product with sales of less than $25 million in the ...